Information Provided By:
Fly News Breaks for March 19, 2019
JAZZ
Mar 19, 2019 | 11:02 EDT
Wells Fargo analyst David Maris raised his 2019 earnings per share estimate for Jazz Pharmaceuticals to $14.58 from $13.81 and 2020 estimate to $16.59 from $16.35 to reflect the company's guidance and annual report. Maris also increased his price target for the shares to $162 from $154. The analyst sees "several catalysts" in 2019 for the stock, including Xyrem launch for pediatric indication in late Q1, JZP-258 topline results for Phase 3 study in narcolepsy in Spring 2019, and the Solriamfetol FDA action date of March 20. Further, investors are looking for a deal to diversify away from Xyrem, and at the end of 2018, Jazz had cash and investments of $825M as well as undrawn capacity on its revolver of $1.6B, Maris tells investors in a research note. He maintains an Outperform rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ